Idogen appoints Hanne Risager Romedahl as new Chief Scientific Officer
Idogen AB (”Idogen”) announces today the appointment of Hanne Risager Romedahl, PhD, as Chief Scientific Officer (CSO), effective 7 May 2018. She succeeds Anette Sundstedt,PhD, who will continue in the company as scientific expert.
Hanne Risager Romedahl has extensive experience from senior leadership positions within research and development in the pharmaceutical industry. She joins Idogen following a role as Senior Vice President of biologics at the German drug development company Evotec International GmbH. Before that Hanne worked for more than 9 years in various leadership roles at Vice President level within the research organization of Novo Nordisk A/S. During this period, she led the founding of several new competency areas and departments. Hanne had an important role in building project portfolios within hematological and immunological diseases. Before that, Hanne worked as leader within the biotech sector. Hanne has a PhD in immunology from the Technical University of Denmark/Michigan State University, USA. Both academically as well as during her whole industrial career, Hanne has substantial research experience with dendritic cells that constitutes the core research area of Idogen.
”I am looking much forward to working with Idogen - it's a great opportunity for me to work again with dendritic cells that I have long experience with. My view is that dendritic cells hold great potential in future novel cell therapy for many serious immune disorders. It is an honor to be trusted the leadership role for the research of such an innovative company as Idogen that develops a whole new pharmaceutical approach" comments Hanne Risager Romedahl.
"With her background as PhD in immunology and a solid pharmaceutical research and managerial experience in the field, Hanne is an important enhancement of Idogen’s research organization. As Anette Sundstedt enters into a role as scientific expert, we maintain continuity and competence within the company, giving Anette the opportunity to focus on the scientific matters" says Idogen CEO Lars Hedbys.
For additional information, please contact:
Lars Hedbys, CEO Idogen AB
Tel: +46 (0)46-275 63 30
This is an English version of an original Swedish press release communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply.
Idogen (AktieTorget: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. Idogen’s most advanced product candidate IDO 8 is designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII (factor VIII). The company´s second project IDO T is developed to prevent kidney transplant rejection. The treatment is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The fact that a short treatment has the potential to yield a long-lasting effect is another great advantage. For more information, visit www.idogen.com